home · filing · 0001021771-21-000087
8-K filed November 8, 2021, 6:59 PM ET
ticker BRTX
CIK 0001505497
other material
confidence high
sentiment positive
materiality 0.75
BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors
BioRestorative Therapies, Inc.
Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
Common stock begins trading on Nasdaq Capital Market under symbol BRTX on November 5, 2021.
Appointed Robert E. Kristal as CFO; granted option for 10,490 shares at $13.50; also elected Patrick F. Williams and David Rosa as directors.
Granted options to officers and directors: Alstodt and Silva each received 42,059 shares; also repriced their existing options from $47.60 to $13.50.
Intends to use proceeds for clinical trials of BRTX-100, ThermoStem R&D, and working capital.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-11-04
Filed November 8, 2021, 6:59 PM ET
Effective November 4, 2021, David Rosa was elected a director of the Company.
Effective 2021-11-04
Filed November 8, 2021, 6:59 PM ET
Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.
Effective 2021-11-04
Filed November 8, 2021, 6:59 PM ET
Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Rosa was elected as Director at BioRestorative Therapies, Inc..
Action elected
Role Director
Exact text from the filing
Effective November 4, 2021, David Rosa was elected a director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Patrick F. Williams was elected as Director at BioRestorative Therapies, Inc..
Action elected
Role Director
Exact text from the filing
Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert E. Kristal was appointed as Chief Financial Officer at BioRestorative Therapies, Inc..
Action appointed
Role Chief Financial Officer
Exact text from the filing
Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001021771-21-000087
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.